
How you can help us grow Endpoints News through the pandemic
We’re lucky at Endpoints News.
Reader engagement is the highest we’ve ever seen as we approach 80,000 daily email subscribers — with over 20% of them under a paid plan. Business operations are strong, with our team of 17 deployed at home offices across the US, Europe, and Asia before it became mandatory. And we can sell advertising to clients who need to reach a hyper-focused audience. It’s a way of reaching out, without touching, that has become increasingly trendy. The virtual nature of our business gives us a few critical advantages in responding to the crisis.
There are challenges, of course.
Live events account for a third of our revenues — or used to, at least. Connecting the biopharma world is a vital part of our mission, and there’s no real substitute for making new personal connections at conferences.
So until we’re able to meet in close quarters again — stretching well into 2021 — all Endpoints events will be virtual. We’re starting with an aggressive slate of virtual Zoom panels featuring the industry’s top leaders. We’ll have more on that soon. And the team is looking at new and innovative ways at delivering these events, beyond the standard video panels. There’s a huge opportunity to reimagine online conferences and the value they bring to both attendees and sponsors.
To be sure, the biopharma industry itself is demonstrating some real resilience in the crisis. That’s important. Biopharma will be back, altered — certainly — but more focused on big things than ever before.
We’re looking forward to writing about that.
While we’ve been focused on covering the outbreak and its impact on the industry — our special niche — we’ve put fewer stories behind the paywall. That will change soon, and we need your support now more than ever.
Upgrading to a premium plan
The best way to support Endpoints News is for your company to purchase an Enterprise subscription. It’s a transparently priced, flat-rate plan that covers all employees at your organization, starting at $1,000/year. That grants access to our entire paywall library and confers a license for your company to reprint and share our content internally as you please.
Individuals can sign up for an Insider plan, which is now $225/year. In addition to the paywall library, Insiders can disable all advertising. If you want to read just the content and nothing else, this is the plan for you.
We’ll continue to offer the bulk of our stories for free access. But any company or individual looking for the complete picture should get a paid subscription. The prices are affordable, transparent, and provide a ton of value.
Most importantly, with both plans, you’re directly supporting the future development of Endpoints News.
It’s our paid subscribers — who’ve been with us years — that put us in the driver’s seat, in charge of our destiny, navigating the big changes ahead for the media business. With your support, we’ll keep building the staff through the tough times ahead.
For those of you who have a paid sub, thank you. For those of you getting one today, be sure that we have never been more appreciative of your support for the independent mission we have carved out for ourselves as we bootstrapped this startup.
You can sign up here. If you have special requests, you can open up a chat with our support team at this page.
And if you need to reach our biopharma audience with a promotional campaign, please drop a line to our revenue chief, Mike Peck (mike@endpointsnews.com). We are open for (virtual) business 24/7.